SCHEDULE 13G/A: Deerfield Entities Maintain Passive Stake in Catalyst Pharmaceuticals, Disclosing 2.63% Ownership

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have jointly filed an amendment to their Schedule 13G, disclosing a continued passive beneficial ownership of 2.63% in Catalyst Pharmaceuticals, Inc.

Summary

• The filing is an Amendment No. 4 to Schedule 13G, updating beneficial ownership information for Catalyst Pharmaceuticals, Inc.
• The reporting persons are Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn.
• These entities collectively beneficially own 3,133,011 shares of Catalyst Pharmaceuticals, Inc. common stock.
• This ownership represents 2.63% of the total class of securities.
• The investment is passive, with all reporting persons holding shared voting and shared dispositive power over the shares.
• The event date that triggered this filing was December 31, 2024.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing (Schedule 13G/A) disclosing passive beneficial ownership, which inherently carries a neutral sentiment as it does not contain performance data, strategic updates, or forward-looking statements from the issuer.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure of a passive investment by an institutional investor group in a publicly traded pharmaceutical company. It does not provide specific insights into broader industry trends or competitive dynamics beyond the ownership stake itself.

Related Party Transactions

• The reporting persons (Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn) have formed a group for the purpose of this filing, as disclosed in Exhibit B, due to their relationships.

Stakeholder Impact

• Minimal impact on shareholders as the filing indicates a passive investment below the 5% threshold, with no stated intent to influence control or operations of Catalyst Pharmaceuticals, Inc.

Key Dates

Keywords

Catalyst Pharmaceuticals, Deerfield Mgmt, Deerfield Management Company, Deerfield Partners, James E. Flynn, Schedule 13G, beneficial ownership, common stock, passive investment, pharmaceuticals